Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 8/20 | 0.38 |
| ▸ | MAOA | P21397 | 7/20 | 0.38 |
| ▸ | KDM1A | O60341 | 5/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6629532 | 0.87 | NOS1 (0.46) | NOS1NOS2TAAR1MAOBMAOA | |
| SCHEMBL11292416 | 0.80 | NOS1 (0.45) | NOS1NOS2TAAR1MAOBMAOA | |
| SCHEMBL1749974 | 0.78 | NOS1 (0.44) | NOS1NOS2TAAR1MAOBMAOA | |
| SCHEMBL10622601 | 0.76 | NOS1 (0.52) | NOS1NOS2TAAR1MAOBMAOA | |
| SCHEMBL11802449 | 0.74 | NOS1 (0.55) | NOS1NOS2TAAR1MAOBMAOA | |
| SCHEMBL11802455 | 0.74 | NOS1 (0.55) | NOS1NOS2TAAR1MAOBMAOA | |
| SCHEMBL11777702 | 0.74 | NOS1 (0.55) | NOS1NOS2TAAR1MAOBMAOA | |
| SCHEMBL15416047 | 0.71 | DDB1 (0.39) | CYP1A2LMNAHSD17B10BLM | |
| SCHEMBL6268220 | 0.70 | MAOB (0.50) | NOS1NOS2TAAR1MAOBMAOA | |
| SCHEMBL6311085 | 0.70 | NOS1 (0.45) | NOS1NOS2TAAR1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120202439-A | Photosensitive element, method for forming resist pattern, and method for manufacturing printed wiring board | 株式会社力森诺科 | 2025-06-24 | — | — | CN | disclosed |
| CN-118475880-A | Alkali-soluble resin, photosensitive resin composition, photosensitive element, method for forming resist pattern, and method for manufacturing printed wiring board | 株式会社力森诺科 | 2024-08-09 | — | — | CN | disclosed |
| US-8664195-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8610998-B2 | Coloured organic electrophoretic particles | BASF SE (DE) | 2013-12-17 | — | — | US | disclosed |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8080536-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7816345-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7629494-B2 | Process for producing cyclopropylphenol derivative | MITSUI CHEMICALS AGRO, INC. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20090054681-A1 | Production Process of cyclopropylphenol derivatives | SANKYO AGRO COMPANY, LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| US-6831083-B2 | For therapy and prophylaxis of cerebral ischemia (cerebral infarct and brain edema), sequela of cerebral ischemia, cephalotrauma, glaucoma, retinopathy, epilepsy and amyotrophic lateral sclerosis (ALS), all caused by glutamic acid toxicity | MITSUI CHEMICALS, INC. (JP) | 2004-12-14 | — | — | US | disclosed |
| US-6752981-B1 | CYCLIC PHOSPH(ORAMID)ATE PRODRUGS HAVING ALCOHOL, AMINE, ORTHIOL GROUPS ATTACHED TO THE PHOSPHORUS IN THE C3N2P OR C3O2P RING | METABASIS THERAPEUTICS, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20030149046-A1 | Pyrazoline derivative or tetrahydropyridazine derivative and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-08-07 | — | — | US | disclosed |
| EP-1270567-A1 | PYRAZOLINE DERIVATIVES OR TETRAHYDROPYRIDAZINE DERIVATIVES AND MEDICINAL USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-1210354-A1 | PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY | Metabasis Therapeutics, Inc. (US) | 2002-06-05 | — | — | EP | disclosed |
| EP-1165570-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | Metabasis Therapeutics, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001018013-A1 | PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY | METABASIS THERAPEUTICS, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000052015-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| EP-0802906-A1 | PROCESS FOR PRODUCING 3,5-DIARYL PYRAZOLENE | BASF AKTIENGESELLSCHAFT (DE) | 1997-10-29 | — | — | EP | disclosed |
| WO-1996021650-A1 | PROCESS FOR PRODUCING 3,5-DIARYL PYRAZOLENE | BASF AKTIENGESELLSCHAFT (DE) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149046-A1 | Pyrazoline derivative or tetrahydropyridazine derivative and medicinal use thereof | SLC1A2, SLC1A1, SLC1A3 | NOS1 473/4885NOS2 575/4885TAAR1 3911/4885 |
| US-20090054681-A1 | Production Process of cyclopropylphenol derivatives | CBR3, CYP4X1, CYP4A11 | NOS1 861/4885NOS2 393/4885TAAR1 845/4885 |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | NOS1 3670/4885NOS2 4006/4885TAAR1 3414/4885 |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | NOS1 3670/4885NOS2 4006/4885TAAR1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.